Drug Trial Radar · NCT04639050
Brainshuttle AD: A Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7126209 Following Intravenous Infusion in Participants With Prodromal or Mild to Moderate Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Sep 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
241
Actual
Start
Mar 15, 2021
Primary completion
Jul 31, 2027
Study completion Jul 31, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 20, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 85 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics of multiple-ascending intravenous (IV) doses of RO7126209 in participants with prodromal or mild to moderate Alzheimer's disease (AD), who are amyloid positive based on amyloid positron emission tomography (PET) scan.
Conditions
- Alzheimers Disease
Interventions
RO7126209Drug
RO7126209 will be administered intravenously as specified in each treatment arm.
PlaceboDrug
RO7126209-matching placebo will be administered intravenously as specified in each treatment arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1, 2, 3, and 4: Percentage of Participants With Adverse Events (AEs)Time frame: Part 1 and 2: Up to approximately 56 weeks; Part 3: Up to approximately 52 weeks; Part 4: Up to approximately 233 weeks
- Part 3: Change From Baseline in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) ScanTime frame: Up to approximately 24 weeks
Locations
37 sites in 9 countries. Site status is shown where the registry gives one.
JEM Research LLC
Atlantis, Florida
K2 Medical Research-Winter Garden
Clermont, Florida
K2 Medical Research - The Villages
Lady Lake, Florida
K2 Medical Research, LLC
Maitland, Florida
Optimus U Corp
Miami, Florida
Charter Research - Winter Park/Orlando
Orlando, Florida
Alzheimer's Research and Treatment Center
Stuart, Florida
Charter Research - Lady Lake/The Villages
The Villages, Florida
Alzheimer?s Research and Treatment Center
Wellington, Florida
Conquest Research, LLC
Winter Park, Florida
Alzheimer's Research and Treatment Center - Columbus
Columbus, Georgia
Center for Advanced Research & Education
Gainesville, Georgia
Quest Research Institute
Farmington Hills, Michigan
Abington Neurological Associates
Abington, Pennsylvania
Kerwin Research Center, LLC
Dallas, Texas
Heidelberg Repatriation Hospital
Heidelberg West, Victoria, Australia
Alfred Hospital
Melbourne, Victoria, Australia
Richmond Clinical Trials
Richmond, British Columbia, Canada
Toronto Memory Program
Toronto, Ontario, Canada
Centro de Investigación Clínica UC-CICUC
Santiago, Chile
Hospital Clinico Univ de Chile
Santiago, Chile
Koseikai Takeda Hospital
Kyoto, Japan
National Hospital Organization Utano National Hospital
Kyoto, Japan
Keio University Hospital
Tokyo, Japan
Tokyo Metropolitan Institute for Geriatrics and Gerontology
Tokyo, Japan
Federation of National Public Service Personnel Mutual Aid Associations Tachikawa Hospital
Tokyo, Japan
Osrodek Badan Klinicznych Euromedis
Szczecin, Poland
NZOZ WCA
Wroc?aw, Poland
Inha University Hospital
Incheon, South Korea
Samsung Medical Center
Seoul, South Korea
Fundación ACE
Barcelona, Spain
Hospital Clinic i Provincial
Barcelona, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Hospital Universitario Dr. Peset
Valencia, Spain
Hospital General De Catalunya
Sant Cugat del Vallès, Barcelona, Spain
Policlínica Guipuzcoa
Donostia / San Sebastian, Guipuzcoa, Spain
UCL Institute of Neurology
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.